Article ID Journal Published Year Pages File Type
8210553 International Journal of Radiation Oncology*Biology*Physics 2018 10 Pages PDF
Abstract
ROs are less likely than other specialties to lead trials that use RT in combination with drug therapy or surgery and more likely to lead trials supported by nonindustry, non-NIH funding. This suggests a need for ROs to lead multimodality trials and to consider opportunities to interact with industry. As NIH resources decrease, alternative funding is needed to support innovation, particularly in in RT-alone trials.
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Authors
, , , , , , , , , , , ,